Enriched Trials May Allow Sponsors To Seek Broad Labels, FDA's Temple Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Enriching a clinical trial by selectively enrolling likely responders may nevertheless allow a sponsor to seek a broad label for the agent, Office of Drug Evaluation I Acting Director Robert Temple, MD, said during an FDA "Critical Path" update Dec. 3
You may also be interested in...
FDA "Critical Path" Faces Roadblock
The agency plans to release its list of top priorities several months behind schedule while it focuses on drug safety issues, Acting Deputy Commissioner Woodcock says. Limited FDA resources may jeopardize the project as well.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.